波动生命科学股价在肥胖药物WVE-007未能满足预期后暴跌. Wave Life Sciences shares plummeted after obesity drug WVE-007 failed to meet expectations at higher doses.

波动生命科学股票在其实验性肥胖药物WVE-007未能满足预期后急剧下降,尽管低剂量显示积极的结果. Wave Life Sciences shares dropped sharply after its experimental obesity drug, WVE-007, failed to meet expectations at a higher dose, despite showing positive results at a lower dose. 公司报告说,六个月的试验数据显示内脏脂肪减少了14%,但投资者反应不佳,导致股票暴跌. The company reported the six-month trial data indicated a 14% reduction in visceral fat, but investors reacted negatively, causing the stock to plummet.